CoChat

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

Open access
Raz, Itamar, Wilson, Peter W.F., Strojek, Krzysztof, Kowalska, Irina, Bozikov, Velimir, Gitt, Anselm K., Jermendy, György, Campaigne, Barbara N., Kerr, Lisa, Milicevic, Zvonko, Jacober, Scott J. · 2009 · Diabetes Care

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI). RESEARCH DESIGN AND METHODS—Patients (type 2 diabetes, aged 30–75 years) were randomly assigned within 21 days after AMI to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l) or the 2) basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l). RESULTS—A total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1–1,687 days). The trial was stopped for lack of efficacy. Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174, 31.2%) and BASAL (n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8–1.21]). Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 ± 0.1 vs. 7.8 ± 0.1%; P = 0.4) during the study. The PRANDIAL group showed a lower daily mean postprandial blood glucose (7.8 vs. 8.6 mmol/l; P < 0.01) and 2-h postprandial blood glucose excursion (0.1 vs. 1.3 mmol/l; P < 0.001) versus the BASAL group. The BASAL group showed lower mean fasting blood glucose (7.0 vs. 8.1 mmol/l; P < 0.001) and similar daily fasting/premeal blood glucose (7.7 vs. 7.3 mmol/l; P = 0.233) versus the PRANDIAL group. CONCLUSIONS—Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc08-1671

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Fraction of patients who did not experience a first primary (combined cardiovascular) adjudicated outcome versus days in trial by treatment strategy (PRANDIAL versus BASAL).
Figure 1 Fraction of patients who did not experience a first primary (combined cardiovascular) adjudicated outcome versus days in trial by treatment strategy (PRANDIAL versus BASAL).CC BY-NC-ND · PubMed Central
Figure 2 Glycemic measures. A: Mean ± SD A1C at each visit by treatment strategy (PRANDIAL versus BASAL). B: Seven-point mean self-monitored blood glucose profiles at baseline (dotted line) and throughout the study (postrandomization, solid line) by treatment strategy (PRANDIAL versus BASAL).
Figure 2 Glycemic measures. A: Mean ± SD A1C at each visit by treatment strategy (PRANDIAL versus BASAL). B: Seven-point mean self-monitored blood glucose profiles at baseline (dotted line) and throughout the study (postrandomization, solid line) by treatment strategy (PRANDIAL versus BASAL).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

Metadata

Authors
Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., & Jacober, S. J.
Affiliations
  • Hadassah Medical Center (IL)
  • Emory University (US)
  • Medical University of Silesia (PL)
  • Medical University of Białystok (PL)
  • Endocrinology, Diabetes and Metabolic Diseases, University Hospital Dubrava, Zagreb, Croatia
  • Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
  • Medical Department, Bajcsy-Zsilinszky Teaching Hospital, Budapest, Hungary
  • Eli Lilly (United States) (US)
  • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
Venue
Diabetes Care
Published
2009-03-01
Volume
32
Issue
3
Pages
381-386
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2172111876
Cited by
351
References
26
Citations by year
2025: 5 · 2024: 9 · 2023: 2 · 2022: 5 · 2021: 12 · 2020: 13 · 2019: 18 · 2018: 20 · 2017: 22 · 2016: 28 · 2015: 36 · 2014: 25 · 2013: 35 · 2012: 24
FWCI
29.32
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Sanofi
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
type 2 diabetes, acute myocardial infarction, insulin lispro, basal insulin, postprandial blood glucose, glycemic excursions, cardiovascular outcomes, HbA1c, lack of efficacy
MeSH terms
Insulin Glargine, Adult, Aged, Body Weight, Cardiovascular System, Diabetes Mellitus, Type 2, Drug Administration Schedule, Fasting, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Treatment Outcome, Postprandial Period, Insulin, Long-Acting, Insulin Lispro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.